INTRODUCTION

Diabetes mellitus (DM) is a common chronic disorder and is one of the leading causes of death worldwide accounting for one death every 6 secs. It is a progressive disorder associated with complications such as metabolic syndrome, cardiovascular disease, nephropathy, stroke, neuropathy, retinopathy and premature deaths, if not managed early and properly in its course. Nutrients such as vitamin C supplementation play an essential role in the prevention and management of DM and other metabolic disorders. Vitamin C is an essential nutrient and an antioxidant with a similar structure of glucose, is not produced by the humans due to the absence of the enzyme, L-gulonolactone oxidase. It is also known as ascorbic acid, a cofactor in multiple enzymatic reactions including collagen synthesis. Dehydroascorbic acid (DHA, oxidized transportable form of vitamin C) uptake into the cells is accomplished through glucose transporters (GLUTs), GLUT1 and GLUT3, which transport DHA in competition with glucose. While hyperglycemia inhibits this cellular uptake of DHA. Hence in a diabetic patient there is deficiency of vitamin C not only due to decreased cellular uptake but also due to

ABSTRACT

Background: Diabetes mellitus (DM) is the most common non-communicable diseases in the present millennium which has become a global public health problem. The treatment of type 2 Diabetes mellitus (T2 DM) often is initiated with monotherapy of oral antidiabetic drugs (OADs), which often do not decrease the plasma sugar levels effectively and consistently that will reduce short term and long-term complications associated with T2 DM. Hence the current study is aimed to determine the effectiveness of vitamin C supplementation with standard OADs on glycemic control.

Methods: This study consisted of 120 T2 DM patients with 80 males and 40 females with a mean age of 50.88 yrs were divided into four groups with equal number of males and females in each group depending upon the OADs they received in solo or with vitamin C for 12 weeks. After the written consent, a detail clinical history, clinical examination, biochemical investigations including fasting plasma sugar (FPS), post prandial plasma sugar (PPS), glycosylated hemoglobin (HBA1c), serum creatinine, serum electrolytes, chest X-ray PA view and standard ECG were done. Repeat FPS, PPS and HBA1c were done after 4, 8 and 12 weeks of study.

Results: After 12 weeks of study FBS, PPS and HBA1c decreased significantly (p < 0.01) in study groups (Metformin and teneligliptin with vitamin C) as compared to control groups (OADs without vitamin C). Vitamin C supplementation with OADs found to be effective, well tolerated and devoid of any side effects.

Conclusions: OADs are effective and affordable hypoglycemic agents with vitamin C supplementation.

Keywords: Supplementation, Effective, Affordable, OADs, Vitamin C
increased urinary losses, and increased metabolic turnover. Consequently deficiency of vitamin C results in the defective formation of collagen and connective tissues and oxidative stress which leads to further disturbed glucose metabolism and enhanced hyperglycemia. Therefore vitamin C supplementation with standard OADs, may have an impact on glycemic control.

Metformin is a biguanide oral anti diabetic drug which inhibits hepatic gluconeogenesis, increases peripheral insulin sensitivity and decreases intestinal glucose absorption.

Teneligliptin, an oral anti diabetic drug is a third-generation class 3 dipeptidyl peptidase (DPP)-4 inhibitor, increases serum insulin levels and decreases serum glucagon levels by increasing the levels of active glucagon like peptide-1 and glucose dependent insulinotropic polypeptide through inhibition of DPP-4 enzymatic activity.

Hence the current study is focused to determine the effectiveness of vitamin C supplementation in achieving glycemic control in T2 DM and thereby preventing/ reducing short term and long-term complications in a DM patient who is on common oral anti diabetic drugs such as metformin or teneligliptin, which are affordable and available to all.

METHODS

This is a prospective comparative study of T2 DM patients conducted in the departments of pharmacology and medicine, Mallareddy institute of medical sciences and hospital, Suraram, Hyderabad, TS from 3rd December 2020 to 11th November 2021, after the Institutional Ethical Committee approval. DM was diagnosed as per 2019 American diabetic association (ADA) guide lines. Patients who were smokers, alcoholic, with coronary artery disease (CAD) and chronic kidney disease were excluded from the study.

After a written consent from each patient, a detailed clinical history, clinical examination, biochemical investigations FPS, PPS, glycosylated hemoglobin (HBA1c), serum creatinine, serum electrolytes, chest X-ray PA view and standard electrocardiogram (ECG) were done. The 2D echocardiogram was done in a few patients with cardiomegaly to rule out ischemic heart disease. Patients were categorized into four groups, each comprising 30 patients (20 males, 10 females).

Study group (Gr) 1: T2 DM patients received metformin (1000 mg BDS) and vitamin C (500 mg BDS) and control group (Gr) 1: T2 DM patients received metformin (1000 mg BDS) only.

Study group (Gr) 2: T2 DM patients received teneligliptin (20 mg/day) and vitamin C (500 mg BDS) and control group (Gr) 2: T2 DM patients received teneligliptin (20 mg/day) only.

Repeat FPS, PPS and HBA1c were done after 4, 8 and 12 weeks of treatment.

Statistical analysis

The data obtained from the study are presented as mean with standard deviation and percentage and results are assessed by using Student’s t test; p<0.05 values are considered as statistical significance.

RESULTS

Clinical profile

This study consisted of 120 T2 DM patients with 80 (66.67%) males and 40(33.33%) females with age ranging from 35 to 65 years with a mean of 50.88±7.6 years. Each group consisted of 30 patients with 20 males and 10 females. (Table 1 and Figure 1).

After a written consent from each patient, a detailed clinical history, clinical examination, biochemical investigations FPS, PPS, glycosylated hemoglobin (HBA1c), serum creatinine, serum electrolytes, chest X-ray PA view and standard electrocardiogram (ECG) were done. The 2D echocardiogram was done in a few patients with cardiomegaly to rule out ischemic heart disease. Patients were categorized into four groups, each comprising 30 patients (20 males, 10 females).

Study group (Gr) 1: T2 DM patients received metformin (1000 mg BDS) and vitamin C (500 mg BDS) and control group (Gr) 1: T2 DM patients received metformin (1000 mg BDS) only.

Study group (Gr) 2: T2 DM patients received teneligliptin (20 mg/day) and vitamin C (500 mg BDS) and control group (Gr) 2: T2 DM patients received teneligliptin (20 mg/day) only.

Repeat FPS, PPS and HBA1c were done after 4, 8 and 12 weeks of treatment.

Statistical analysis

The data obtained from the study are presented as mean with standard deviation and percentage and results are assessed by using Student’s t test; p<0.05 values are considered as statistical significance.

RESULTS

Clinical profile

This study consisted of 120 T2 DM patients with 80 (66.67%) males and 40(33.33%) females with age ranging from 35 to 65 years with a mean of 50.88±7.6 years. Each group consisted of 30 patients with 20 males and 10 females. (Table 1 and Figure 1).

After a written consent from each patient, a detailed clinical history, clinical examination, biochemical investigations FPS, PPS, glycosylated hemoglobin (HBA1c), serum creatinine, serum electrolytes, chest X-ray PA view and standard electrocardiogram (ECG) were done. The 2D echocardiogram was done in a few patients with cardiomegaly to rule out ischemic heart disease. Patients were categorized into four groups, each comprising 30 patients (20 males, 10 females).

Study group (Gr) 1: T2 DM patients received metformin (1000 mg BDS) and vitamin C (500 mg BDS) and control group (Gr) 1: T2 DM patients received metformin (1000 mg BDS) only.

Study group (Gr) 2: T2 DM patients received teneligliptin (20 mg/day) and vitamin C (500 mg BDS) and control group (Gr) 2: T2 DM patients received teneligliptin (20 mg/day) only.

Repeat FPS, PPS and HBA1c were done after 4, 8 and 12 weeks of treatment.

Statistical analysis

The data obtained from the study are presented as mean with standard deviation and percentage and results are assessed by using Student’s t test; p<0.05 values are considered as statistical significance.
**Plasma sugars**

**Initial**

**FPS:** The initial FPS ranged between 138 to 200 mg/dl with a mean of 180.35±20.2 (Table 2).

**PPS:** Similarly, the initial PPS ranged between 204 to 300 mg/dl with a mean of 269.38±30.18 (Table 3).

**HBA1c:** So also, the initial HBA1c in this study ranged between 7.4-9.6% with a mean of 8.5±0.9 (Table 4).

The mean FPS, PPS and HBA1c were slightly higher in females as compared to males in all groups.

**After 4 weeks of study**

**FPS:** The mean FPS decreased by 10.5 mg/dl (5.84%) in study Gr 1 as compared to 7.1 mg/dl (3.95%) in control Gr 1. Similarly, the mean FPS decreased by 10.6 mg/dl (5.89%) in study Gr 2 as compared to 7.4 mg/dl (4.12%) in control Gr 2 (Table 5).

**PPS:** The mean PPS decreased by 16.3 mg/dl (6.09%) in study Gr 1 as compared to 10.7 mg/dl (3.97%) in control Gr 1. So, also the mean PPS decreased by 22 mg/dl (8.11%) in study Gr 2 as compared to 12.1 mg/dl (4.49%) in control Gr 2 (Table 6). The decrease of PPS was statistically significant in both study groups with vitamin C.

**HBA1c:** Mean HBA1c decreased by 0.4% (4.71%) in study Gr 1 as compared to 0.3% (3.57%) in control Gr 1. Similarly, mean HBA1c decreased by 0.5% (5.81%) study Gr 2 compared to 0.3% (3.53%) in control Gr 2 (Table 7). The decrease of mean PPS was statistically significant in all groups, while FPS was statistically significant in all groups, while PPS was statistically significant in all groups.

**After 8 weeks of study**

**FPS:** The mean FPS decreased by 18.4 mg/dl (10.24%) in study Gr 1 as compared to 14.1 mg/dl (7.85%) in control Gr 1. Similarly, the mean FPS decreased by 19.9 mg/dl (11.05%) in study Gr 2 as compared to 14.4 mg/dl (8.01%) in control Gr 2 (Table 5). The decrease of mean FPS was statistically significant in all groups, while FPS <126 mg/dl occurred in 6 (20%) and 7 (23.33%) patients of study Gr 1 and study Gr 2 respectively.

**PPS:** The mean PPS decreased by 30 mg/dl (11.21%) in study Gr 1 as compared to 22.1 mg/dl (8.21%) in control Gr 1. So, also the mean PPS decreased by 35.5 mg/dl (13.09%) in study Gr 2 as compared to 25 mg/dl (9.3%) in control Gr 2 (Table 6). The decrease of mean PPS was statistically significant in all groups, while PPS <200 mg/dl was achieved in 8 (26.67%) and 9 (30%) in study groups 1 and 2 respectively as compared to 4 (13.33%) and 5 (16.67%) in control groups 1 and 2 respectively.

**HBA1c:** The mean HBA1c decreased by 0.9% (9.41%) in study Gr 1 as compare to 0.6% (7.14%) in control Gr 1. Similarly, the mean HBA1c decreased by 1.0% (11.63%) in study Gr 2 as compared to 0.6% (7.06%) in control Gr 2 (Table 7). The decrease of mean HBA1c was statistically significant in all groups of patients. However, HBA1c <6.5% of HBA1c occurred in 6 (20%) and 7 (23.33%) patients in study groups 1 and 2 respectively as compared to 2 (6.67%) and 3 (10%) in control groups 1 and 2 respectively.

**After 12 weeks of study**

**FPS:** The mean FPS decreased by 22.2 mg/dl (12.35%) in study Gr 1 as compared to 16.1 mg/dl (8.96%) in control Gr 1. Similarly the mean FPS decreased by 28 mg/dl (15.55%) in study Gr 2 as compared to 17.3 mg/dl (9.62%) in control Gr 2 (Table 5). The decrease of mean FPS was statistically significant in all groups. The FPS <126 mg/dl occurred in 9 (30%) and 11 (36.67%) patients of study groups 1 and 2 respectively while it occurred in 4 (13.33%) and 5 (16.67%) patients of control groups 1 and 2 respectively.

**PPS:** The mean PPS decreased by 35.2 mg/dl (13.16%) in study Gr 1 as compared to 25.2 mg/dl (9.36%) in control Gr 1. So, also the mean PPS decreased by 44.0 mg/dl (16.22%) in study Gr 2 as compared to 28 mg/dl (10.39%) in control Gr 2 (Table 6). PPS <200 mg/dl was achieved in 10 (33.33%) and 11 (36.67%) in study groups 1 and 2 respectively as compared to 5 (16.66%) and 6 (20%) in control groups 1 and 2 respectively. The decrease of mean PPS was statistically significant in all groups of patients.

**HBA1c:** The mean HBA1c decreased by 1.4% (16.47%) in study Gr 1 as compare to 1.0% (11.90%) in control Gr 1. Similarly, the mean HBA1c decreased by 1.5% (17.44%) in study Gr 2 as compared to 1.0% (11.76%) in control Gr 2 (Table 7). The decrease of mean HBA1c was statistically significant in all groups of patients. HBA1c <6.5% occurred in 8 (26.67%) and 9 (30%) patients in study groups 1 and 2 respectively as compared to 3 (10%) and 4 (13.33%) in control groups 1 and 2 respectively.

**Table 1: Age and duration of DM in type 2 diabetic patients.**

| Parameters          | Control group 1 (Metformin) | Study group 1 (Metformin and vit C) | Control group 2 (Teneligliptin) | Study group 2 (Teneligliptin and vit C) |
|---------------------|-----------------------------|-------------------------------------|---------------------------------|----------------------------------------|
| Age (years)         | Range 35-63                 | Range 35-64                         | Range 35-65                     | Range 35-68                             |
|                     | Mean 49.75±7.7              | Mean 50.57±8.1                      | Mean 51.83±8.3                  | Mean 49.68±6.1                          |
| DM duration (years) | Range 2-9                   | Range 2-9                           | Range 2-8                       | Range 2-10                              |
|                     | Mean 4.2±1.3                | Mean 4.7±1.8                        | Mean 4.4±1.5                    | Mean 4.3±1.6                            |
### Table 2: Fasting plasma sugar and oral antidiabetic drugs.

| Blood sugar | Control group 1 (Metformin) | Study group 1 (Metformin and vit C) | Control group 2 (Teneligliptin) | Study group 2 (Teneligliptin and vit C) |
|-------------|-----------------------------|-----------------------------------|-------------------------------|-----------------------------------|
| FPS (mg/dl) |                             |                                   |                               |                                   |
| Initial     | Range 140-200               | 138-200                           | 142-200                       | 142-199                           |
|             | Mean 179.6±20.1             | 179.7±22.2                       | 179.8±21.2                   | 180.1±19.3                       |
| After 4 wks | Range 134-193               | 134-194                           | 136-192                       | 133-167                           |
|             | Mean 172.5±21.2             | 169.2±21.3                       | 172.4±20.1                   | 169.5±19.2                       |
| After 8 wks | Range 128-184               | 120-176                           | 130-184                       | 121-165                           |
|             | Mean 165.5±22.2             | 161.3±20.1                       | 165.4±21.2                   | 160.2±18.4                       |
| After 12 wks| Range 125-180               | 125-172                           | 124-178                       | 119-157                           |
|             | Mean 163.5±23.4             | 157.5±25.3                       | 162.5±23.4                   | 152.1±22.2                       |

### Table 3: Post prandial plasma sugar and oral antidiabetic drugs.

| Blood sugar | Control group 1 (Metformin) | Study group 1 (Metformin and vit C) | Control group 2 (Teneligliptin) | Study group 2 (Teneligliptin and vit C) |
|-------------|-----------------------------|-----------------------------------|-------------------------------|-----------------------------------|
| PPS (mg/dl) |                             |                                   |                               |                                   |
| Initial     | Range 210-300               | 204-285                           | 213-300                       | 214-295                           |
|             | Mean 269.3±33.4             | 267.5±25.3                       | 269.5±31.5                   | 271.2±30.5                       |
| After 4 wks | Range 201-294               | 191-267                           | 200-282                       | 195-274                           |
|             | Mean 258.6±32.3             | 251.2±25.4                       | 257.4±32.3                   | 249.2±29.6                       |
| After 8 wks | Range 193-281               | 181-253                           | 193-273                       | 185-259                           |
|             | Mean 247.2±31.5             | 237.4±21.2                       | 244.5±30.5                   | 235.7±25.3                       |
| After 12 wks| Range 189-275               | 177-247                           | 187-264                       | 174-244                           |
|             | Mean 244.1±32.2             | 232.3±20.1                       | 241.5±29.6                   | 227.2±23.4                       |

### Table 4: Glycosylated hemoglobin and oral antidiabetic drugs.

| Blood sugar | Control group 1 (Metformin) | Study group 1 (Metformin and vit C) | Control group 2 (Teneligliptin) | Study group 2 (Teneligliptin and vit C) |
|-------------|-----------------------------|-----------------------------------|-------------------------------|-----------------------------------|
| HBA1c (%)   |                             |                                   |                               |                                   |
| Initial     | Range 7.4-9.6               | 7.7-9.6                           | 7.6-9.6                       | 7.6-9.6                           |
|             | Mean 8.4±0.7                | 8.5±0.9                           | 8.5±0.9                       | 8.6±1.0                           |
| After 4 wks | Range 7.1-9.2               | 7.3-8.9                           | 7.3-9.0                       | 7.1-9.0                           |
|             | Mean 8.1±0.8                | 8.1±0.8                           | 8.2±0.8                       | 8.1±0.9                           |
| After 8 wks | Range 6.9-8.8               | 6.8-8.5                           | 7.0-8.7                       | 6.7-8.4                           |
|             | Mean 7.8±0.9                | 7.7±0.7                           | 7.9±0.8                       | 7.6±0.7                           |
| After 12 wks| Range 6.5-8.0               | 6.4-7.9                           | 6.5-8.4                       | 6.3-7.6                           |
|             | Mean 7.4±0.6                | 7.1±0.5                           | 7.5±0.2                       | 7.1±0.4                           |

### Table 5: Effects of oral antidiabetic drugs on fasting plasma sugar.

| Blood sugar Parameter: FPS (mg/dl) | Control group 1 (Metformin) | Study group 1 (Metformin and vit C) | Control group 2 (Teneligliptin) | Study group 2 (Teneligliptin and vit C) |
|-----------------------------------|-----------------------------|-----------------------------------|-------------------------------|-----------------------------------|
| Initial mean                      | 179.6                       | 179.7                             | 179.8                         | 180.1                             |
| After 4 wks                       | 172.5                       | 169.2                             | 172.4                         | 169.5                             |
| % of ↓ 3.95%                      | -7.1; 5.84%                 | -10.5; 4.12%                     | -7.4; 4.12%                   | -10.6; 5.89%                     |
| After 8 wks                       | 165.5                       | 161.3                             | 165.4                         | 160.2                             |
| % of ↓ 7.85%, (p<0.05)            | -14.1; 10.24%, (p<0.01)     | -18.4; 10.01%, (p<0.01)          | -14.4; 8.01%, (p<0.05)        | -19.9; 11.05%, (p<0.01)          |
| After 12 wks                       | 163.5                       | 157.5                             | 162.5                         | 152.1                             |
| % of ↓ 8.96%, (p<0.05)            | -16.1; 9.62%, (p<0.05)      | -22.2; 12.35%, (p<0.01)          | -17.3; 9.62%, (p<0.05)        | -28.0; 15.55%, (p<0.01)          |
Table 6: Effects of oral antidiabetic drugs on postprandial plasma sugar.

| Blood sugar parameter: PPS (mg/dl) | Control group 1 (Metformin) | Study group 1 (Metformin and vit C) | Control group 2 (Teneligliptin) | Study group 2 (Teneligliptin and vit C) |
|-----------------------------------|-----------------------------|------------------------------------|-------------------------------|---------------------------------------|
| Initial mean                      | 269.3                       | 267.5                              | 269.5                         | 271.2                                 |
| After 4 wks                       | 258.6                       | 251.2                              | 257.4                         | 249.2                                 |
| % of ↓                            | -10.7; 3.97%                | -16.3; 6.09% (p<0.05)              | -12.1; 4.49%                  | -22; 8.11% (p<0.05)                   |
| After 8 wks                       | 247.2                       | 237.5                              | 244.5                         | 235.7                                 |
| % of ↓                            | -22.1; 8.21% (p<0.05)       | -30; 11.21% (p<0.01)               | -25; 9.3% (p<0.05)            | -35.5; 13.09% (p<0.01)                |
| After 12 wks                      | 244.1                       | 232.3                              | 241.5                         | 227.2                                 |
| % of ↓                            | -25.2; 9.36% (p<0.05)       | -35.2; 13.16% (p<0.01)             | -28; 10.39% (p<0.01)          | -44; 16.22% (p<0.001)                 |

Table 7: Effects of oral antidiabetic drugs on HBA1c.

| Blood sugar parameter: HBA1c (%) | Control group 1 (Metformin) | Study group 1 (Metformin and vit C) | Control group 2 (Teneligliptin) | Study group 2 (Teneligliptin and vit C) |
|----------------------------------|-----------------------------|------------------------------------|-------------------------------|---------------------------------------|
| Initial mean                     | 8.4                         | 8.5                                | 8.5                           | 8.6                                   |
| After 4 wks                      | 8.1                         | 8.1                                | 8.2                           | 8.1                                   |
| % of ↓                           | -0.3; 3.57%                 | -0.4; 4.71%                       | -0.3; 3.53%                   | -0.5; 5.81%                          |
| After 8 wks                      | 7.8                         | 7.7                                | 7.9                           | 7.6                                   |
| % of ↓                           | -0.6;7.14% (p<0.05)         | -0.9; 9.41% (p<0.05)               | -0.6;7.06% (p<0.05)           | -1.0; 11.63% (p<0.01)                 |
| After 12 wks                      | 7.4                         | 7.1                                | 7.5                           | 7.1                                   |
| % of ↓                           | -1.0; 11.90% (p<0.01)       | -1.4; 16.47% (p<0.001)             | -1.0; 11.76% (p<0.01)         | -1.5; 17.44% (p<0.001)                |

DISCUSSION

In this study mean FPS, mean PPS and mean HBA1c decreased significantly in study groups of metformin and teneligliptin with vitamin C without any side effects as compared to control groups. FPS <126 mg/dl after 12 weeks occurred in 30% and 36.67% patients of study groups with metformin and vitamin C and teneligliptin with vitamin C respectively.

Similarly, after 12 weeks PPS <200 mg/dl was achieved in 33.33% and 36.67%, in study groups with metformin and vitamin C and teneligliptin with vitamin C respectively.

Mean HBA1c decreased by 16.47-17.44% in patients who received vitamin C along with OADs and HBA1c<6.5% occurred in 26.67% and 30% patients in study groups of metformin with vitamin C and teneligliptin with vitamin C respectively.

Similarly, Eriksson et al reported that Ascorbic acid improved glycemic control, lowering both FPS and HBA1c. So, also Sargent et al in their prospective population-based study from 1995 to 1998 in Norfolk, UK found an inverse association between plasma vitamin C and HBA1c, and recommended dietary measures to increase plasma vitamin C as an important health strategy for reducing the prevalence of DM.

Our study results are also in agreement with previously published data showing betterment in glycemic control with vitamin C supplementation in STZ-rats by Sridulyakul et al and decreased of HBA1c and blood glucose in type 2 diabetic patients supplemented with vitamin C by Ardekani et al.

Dakhale et al also found addition of 500 mg twice daily vitamin C supplementation to standard therapy in 70 patients treated with metformin for T2 DM for 12 weeks, lower HBA1c, fasting and post-meal blood glucose levels when compared to the placebo group.

So, also Bhatt et al in their study on 62 T2 diabetic patients for 3months found that vitamin C supplementation significantly decreased the total cholesterol and LDL cholesterol besides also decreased HBA1c and fasting blood sugar though not statistically significant.

A meta-analysis of 5 RCTs by Tabatabaei-Malazy et al found a significant effect on FBS, and non-significant effect on HBA1c from a single intake of ascorbic acid versus placebo.

Similarly, a meta-analysis by AW Ashor et al noted administration of vitamin C for more than 30 days in T2 DM patients significantly reduced FPS as compared to
postprandial insulin concentration and advocated supplementation of vitamin C in T2 DM patients.20

The beneficial effects of supplementation of vitamin C in T2 DM are (1) due to its free radical-scavenging antioxidants effect and (2) vitamin C-mediated increase in insulin action mainly due to its improvement in nonoxidative glucose metabolism.21

The study of effect of vitamin C in T2 DM patients who are also managed with OADs and insulin/or Insulin only were not included in this study as there were not enough patients due to COVID-19 pandemic, besides most of these patients ideally require inpatient management for better follow up and conclusion. A larger number of patients and inclusion of T2 DM patients who are managed with insulin/insulin and OADs in this study could have given wider implications and recommendations for supplementation of vitamin C in the management of DM

CONCLUSION

DM is the most common non-communicable diseases in the present millennium which has become a global public health problem and a leading cause of death worldwide. DM is also a chronic and progressive disorder associated with complications and premature deaths, if not managed early and properly in its course. Supplementation of vitamin C, an essential nutrient and an antioxidant, with a similar structure of glucose play an essential role in the prevention and management of DM. In a diabetic patient there is deficiency of vitamin C not only due to decreased cellular uptake but also due to increased urinary losses, and increased metabolic turnover. Hence in this study, supplementation of vitamin C with metformin and teneligliptin was well tolerated and devoid of any side effects; besides its cheaper cost and improvement in FPS, PPS, and HBA1c, make it attractive therapeutic adjuvant in the treatment of type 2 DM; and may provide a simple means of preventing and ameliorating the complications of diabetes mellitus.

ACKNOWLEDGEMENTS

Authors would like to thank HOD of medicine, medical superintendent and management of Mallareddy institute of medical sciences and hospital, Suraram, Hyderabad for permitting us to conduct this study in the medical wards and OPD, and to all our patients who fully co-operated in conducting this study.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. IDF Diabetes Atlas, 7th Edn. Brussels, Belgium: International Diabetes Federation. 2015:3:55.
2. Kumar A, Nagtilak S, Sivakanesan R, Gunasekera S. Cardiovascular Risk Factors in Elderly Normolipidemic Acute Myocardial Infarct Patients-A Case Controlled Study from India. Southeast Asian J Trop Med Public Health. 2009;40(3):581-92.
3. Mandl J, Szarka A, Banhegyi G. Vitamin C: update on physiology and pharmacology. Br J Pharmacol. 2009;157(7):1097-10.
4. Mann GV. Hypothesis: the role of vitamin C in diabetic angiopathy. Perspect Biol Med. 1974;17(2):210-7.
5. Ronchetti IP, Quaglino D Jr, Bergamini G. Ascorbic acid and connective tissue. Subcell Biochem. 1996;25:249-64.
6. Rumsey SC, Kwon O, Xu GW, Burant CF, Simpson I, Levine M. Glucose transporter isoforms GLUT1 and GLUT3 transport dehydroascorbic acid. J Biol Chem. 1997;272(30):18982-9.
7. Vera JC, Rivas CI, Fischbarg J, Golde DW. Mammalian facilitative hexose transporters mediate the transport of dehydroascorbic acid. Nature. 1993;364(6432):79-82.
8. Stankova L, Riddle M, Larmed J. Plasma ascorbate concentrations and blood cell dehydroascorbate transport in patients with diabetes mellitus. Metabolism. 1984;33(4):347–353.
9. Mann GV, Newton P. The membrane transport of ascorbic acid. Ann N Y Acad Sci. 1975;258:243-52.
10. Will JC, Byers T. Does diabetes mellitus increase the requirement for vitamin C? Nutr Rev. 1996;54(7):193-202.
11. Opara EC. Role of oxidative stress in the etiology of type 2 diabetes and the effect of antioxidant supplementation on glycemic control. J Investig Med. 2004;52(1):19-23.
12. American Diabetic Association. Diagnosis and Classification of diabetes mellitus: Standards of Medical Care in Diabetes. Diabetes Care.2019;42(1):S13-28.
13. Eriksson J, Kolivakka A. Magnesium and ascorbic acid supplementation in diabetes mellitus. Ann Nutri Metabolism. 1995;39(4):217-23.
14. Sargent LA, Wareham NJ, Bingham S, Day NE, Luben RN, Oakes S et al. Vitamin C and hyperglycemia in the European Prospective Investigation into Cancer-Norfolk (EPIC-Norfolk) study: a population-based study. Diabetes Care. 2000;23:726-32.
15. Sridulyakul P, Chakraphan D, Patumrakaj S. Vitamin C supplementation could reverse diabetes-induced endothelial cell dysfunction in mesenteric microcirculation in STZ-rats. Clin Hemorheol Microcirculation. 2006;34(1-2):315-21.
16. Ardekani MA, Mohiti J, Amirchaghmaghi E, Modarresi M. The effect of vitamin C supplementation on insulin level, HBA1c and blood glucose in type 2 diabetic patients. J Kerman University Med Sci. 2006;11:12-8.
17. Dakhale GN, Chaudhari HV, Shrivastava M. Supplementation of vitamin C reduces blood glucose
and improves glycosylated hemoglobin in type 2 diabetes mellitus: a randomized, double-blind study. Adv Pharmacol Sci. 2011;2011:195-271.

18. Bhatt JK, Thomas S, Nanjan MJ. Effect of oral supplementation of vitamin C on glycemic control and lipid profile in patients with type 2 diabetes mellitus. Int J Pharm Pharm Sci. 2012;4:524-7.

19. Tabatabaei-Malazy O, Nikfar S, Larijani B, Abdollahi M. Influence of Ascorbic Acid Supplementation on Type 2 Diabetes Mellitus in Observational and Randomized Controlled Trials: A Systematic Review with Meta-Analysis. J Pharm Pharm Sci. 2014;17(4):554-82.

20. Ashor AW, Werner AD, Lara J, Wills ND, Mthers JC, Siervo M. Effects of vitamin C supplementation on glycaemic control: a systemic and meta-analysis of randomized controlled trials. E J Clin Nutri. 2017;71:1371-80.

21. Eriksson J, Kohvakka A, Kagan VE, Melhem M, Studer RK. Effects of supplementation with vitamin C or E on albuminuria, glomerular IGF-β and glomerular size in diabetics. J Amer Soci Nephrol. 1997;89(9):1405-14.

Cite this article as: Eda S, Motgi S, Singh R, Rao VRBN. Study of role of vitamin C in type 2 diabetes mellitus patients. Int J Basic Clin Pharmacol 2022;11:58-64.